Determinants in chemosensitivity of oncogene-transformed NIH3T3 cells to 2′-C-cyano-2′-deoxy-1-β-D-arabinofuranosylcytosine

International Journal of Oncology

Volumn 14, Issue 3, 1999, Pages 543-549

  Zhang, Min ^a   Endo, Yoshio ^a   Sasaki, Takuma ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

2 C cyano 2 deoxy 1 D arabinofuranosylcytosine; Chemosensitivity; Cytidine deaminase; Deoxycytidine kinase; Membrane transportation; Oncogene transformed cell

Indexed keywords

2' CYANO 2' DEOXYARABINOFURANOSYLCYTOSINE; 2'-CYANO-2'-DEOXYARABINOFURANOSYLCYTOSINE; ANTINEOPLASTIC AGENT; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; DRUG DERIVATIVE; TRITIUM;

ANIMAL; ARTICLE; CANCER TRANSPLANTATION; CELL DIVISION; CELL STRAIN 3T3; CELL TRANSFORMATION; CHICK EMBRYO; DRUG EFFECT; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; GENETIC TRANSFORMATION; METABOLISM; MOUSE; NUDE MOUSE; ONCOGENE; PATHOLOGY;

3T3 CELLS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; CHICK EMBRYO; CYTARABINE; CYTIDINE DEAMINASE; DEOXYCYTIDINE KINASE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ONCOGENES; TRANSFORMATION, GENETIC; TRITIUM;

EID: 0033094049     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Matsuta A, Nakajima Y, Azuma A, Tanaka M and Sasaki T: Nucleosides and nucleotides. 100. 2′-C-Cyano-2′-deoxy-1-β-D-arabinofuranosycytosine (CNDAC) design of potential mechanism-based DNA-strand-breaking antineoplastic nucleoside. J Med Chem 34: 2917-2919, 1991.
2. Tanaka M, Matsuda A, Terao T and Sasaki T: Antitumor activity of a novel nucleoside, 2′-C-cyano-2′-deoxy-1-β-D-arabinofuranosycytosine (CNDAC) against murine and human tumors. Cancer Lett 64: 67-74, 1992.
3. Azuma A, Hanaoka K, Kurihara A, Kobayashi T, Miyauchi S, Kamo N, Tanaka M, Sasaki T and Matsuda A: Nucleosides and Nucleotides. 141. Chemical stability of a new antitumor nucleoside 2′-C-cyano-2′-deoxy-1-β-D-arabino-pentofuranosylcytosine in alkaline medium: Formation of 2′-C-cyano-2′-deoxy-1-β-D-ribo-pentofuranosylcytosine and its antitumor activity. J Med Chem 38: 3391-3397, 1995.
4. Owens JK, Shewach DS, Ullman B and Mitchell BS: Resistance to 1-β-D-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the doxycytidine kinase gene. Cancer Res 52: 2389-2393, 1992.
5. Ruiz van Haperen VWT, Veerman G, Eriksson S, Boven E, Stegmann APA, Hermsen M, Vermorken JB, Pinedo HM and Peters GJ: Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. Cancer Res 54: 4138-4143, 1994.
6. Obata T, Endo Y, Tanaka M, Matsuda A and Sasaki T: Development and biochemical characterization of a 2′-C-cyano-2′-deoxy-β-D-arabinofuranosyl-cytosine (CNDAC)-resistant variant of the human fibroscarcoma cell line HT 1080. Cancer Lett 123: 53-61, 1998.
7. Bishop JM: Cellular oncogenes and retroviruses. Ann Rev Biochem 52: 301-354, 1983.
8. Anderson MW, Reynolds SH, You M and Maronpot RM: Role of proto-oncogene activation in carcinogenesis. Environ Health Perspect 98: 13-24, 1992.
9. Hesketh R: The oncogene handbook. Academic Press Inc., London, 1994.
10. Sklar MD: Increased resistance to cis-diamminedichloroplatinum(II) in NIH 3T3 cells transformed by ras oncogenes. Cancer Res 48: 793-797, 1988.
11. Isonishi S, Hom DK, Thiebaut FB, Mann SC, Andrews PA, Basu A, Lazo JS, Eastman A and Howell SB: Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin. Cancer Res 51: 5903-5909, 1991.
12. Christen RD, Isonishi S, Jones JA, Jekunen AP, Hom DK, Kröniing R, Gately DP, Thiebaut FB, Los G and Howell SB: Signaling and drug sensitivity. Cancer Metastasis Rev 13: 175-189, 1994.
13. Chapman RS, Whetton AD and Dive C: The suppression of drug-induced apoptosis by activition of v-ABL protein tyrosine kinase. Cancer Res 54: 5131-5137, 1994.
14. Gao XS, Asaumi J, Kawasaki S, Nishikawa K, Kuroda M, Takcda Y, Hiraki Y, Ihara M and Ohnishi T: Sensitivity of anticancer drugs in NIH 3T3 cells transfected with oncogene accompanied by pSV2neo vector. Anticancer Res 15: 1911-1914, 1995.
15. Gao XS, Asaumi J, Kawasaki S, Nishikawa K, Kuroda M, Li H, Takeda Y, Hiraki Y, Ihara M and Ohnishi T: Effect of cepharanthin and hyperthermia on the intracellular accumulation of adriamycin in the NIH 3T3 cell lines transfected with oncogene accompanied by pSV2neo vector. Anticancer Res 15: 1991-1996, 1995.
16. Kuo ML, Chou YW, Chau YP and Meng TC: Differential induction of apoptosis in oncogene-transformed NIH 3T3 cells by methylmethanesulfonate. Biochem Pharmacol 52: 481-488, 1996.
17. Koo HM, Monks A, Mikheev A, Rubinstein LV, Gray-Goodrich M, McWilliams MJ, Alvord WG, Oie HK, Gazdar AF, Paull KD, Zarbl H and Vande Woude GF: Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res 56: 5211-5216, 1996.
18. Noda M, Selinger Z, Scolnick EM and Bassin RH: Flat revenants isolated from Kirsten sarcoma virus-transformed cells are resistant to the action of specific oncogenes. Proc Natl Acad Sci USA 80: 5602-5606, 1983.
19. Muschel RJ, Williams JE, Lowy DR and Liotta LA: Harvey ras induction of metastatic potential depends upon oncogene activation and the type of recipient cell. Am J Pathol 121: 1-8, 1985.
20. Anderson SM and Scolnick EM: Construction and isolation of a transforming murine retrovirus containing the src gene of Rous sarcoma virus. J Virol 46: 594-605, 1983.
21. Carmichael J, Degraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay; assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987.
22. Endò Y, Seiki M, Uchida H, Noguchi M, Kida Y, Sato H, Mai M and Sasaki T: Experimental metastasis of oncogene-transformed NIH 3T3 cells in chick embryo. Jpn J Cancer Res 83: 274-280, 1992.
23. Momparler RL and Laliberte J: Induction of cytidine deaminase in HL-60 myeloid leukemic cells by 5-aza-2′-deoxycytidine. Leukemia Res 14: 751-754, 1990.
24. Krenitsky TA, Tuttle JV, Koszalka GW, Chen IS, Beacham III LM, Rideout JL and Elion GB: Deoxycytidine kinase from calf thymus. J Biol Chem 251: 4055-4061, 1976.
25. Datta NS, Shewach DS, Hurley MC, Mitchell BS and Fox IH: Human T-lymphoblast deoxycytidine kinase: purification and properties. Biochemistry 28: 114-123, 1989.
26. Chottiner EG, Shewach DS, Datta NS, Ashcraft E, Gribbin D, Ginsburg D, Fox IH and Mitchell BS: Cloning and expression of human deoxycytidine kinase cDNA. Proc Natl Acad Sci USA 88: 1531-1535, 1991.
27. Arnér ESJ and Eriksson S: Mammalian deoxyribonucleoside kinases. Pharmac Ther 67: 155-186, 1995.
28. Hengstschläger M, Denk C and Wawra E: Cell cycle regulation of deoxycytidine kinase evidence for post-transcriptional control. FEBS Lett 321: 237-240, 1993.
29. Wang LM and Kucera GL: Deoxycytidine kinase is phosphorylated in vitro by protein kinase Ca. Biochim Biophys Acta 1224: 161-167, 1994.
30. Peters GJ, Wets M, Keepers YPAM, Oskam R, Van Ark-Otte J, Noordhuis P, Smid K and Pinedo HM: Transformation of mouse fibroblasts with the oncogenes H-ras or trk is associated with pronounced changes in drug sensitivity and metabolism. Int J Cancer 54: 450-455, 1993.
31. Griffith DA and Jarvis SM: Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1286: 153-181, 1996.
32. Flier JS, Mueckler MM, Usher P and Lodish HF: Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 235: 1492-1495, 1987.